XML 27 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 1 Months Ended | 11 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jan. 26, 2024 | Dec. 31, 2024 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure |  |  |  |  |  |  |
Pay vs Performance Disclosure, Table |  |  | PAY VERSUS PERFORMANCE In accordance with Item 402(v) of Regulation S-K, the Company is required to disclose pay versus performance by comparing compensation amounts previously reported for the last five calendar years to the SEC’s definition of “Compensation Actually Paid” for such years. Also as required by the SEC, this section compares Compensation Actually Paid to various measures used to gauge performance at SIGA. Compensation Actually Paid is a required disclosure item, the amount of which is calculated in accordance with SEC rules. Such measure was not incorporated into the philosophy and strategy of compensation-setting set forth in the “Compensation Discussion and Analysis” of this proxy statement.
Pay Versus Performance Table
Year |  |  | Summary Compensation Table Total for PEO1 |  |  | Compensation Actually Paid to PEO2 |  |  | Average Summary Compensation Table Total for Non-PEO Named Executive Officers3 |  |  | Average Compensation Actually Paid to Non-PEOs Named Executive Officers4, |  |  | Value of initial fixed $100 investment based on: |  |  | Net Income |
| Total Shareholder Return |  |  | Peer Group Total Shareholder Return5 |  |  | Product Sales and Supportive Services Revenues6
2024 |  |  | $4,588,317 |  |  | $5,640,511 |  |  | $1,412,611 |  |  | $1,351,882 |  |  | $159 |  |  | $114 |  |  | $59,214,216 |  |  | $133,330,181
2023 |  |  | $1,825,856 |  |  | $1,825,856 |  |  | $1,399,930 |  |  | $1,373,478 |  |  | $135 |  |  | $115 |  |  | $68,068,826 |  |  | $130,668,209
2022 |  |  | $1,738,912 |  |  | $1,738,912 |  |  | $993,871 |  |  | $993,871 |  |  | $164 |  |  | $111 |  |  | $33,904,806 |  |  | $86,661,583
2021 |  |  | $1,688,264 |  |  | $1,688,264 |  |  | $1,285,045 |  |  | $1,269,045 |  |  | $158 |  |  | $125 |  |  | $69,450,766 |  |  | $126,802,536
2020 |  |  | $1,639,090 |  |  | $1,639,090 |  |  | $1,280,950 |  |  | $1,354,729 |  |  | $152 |  |  | $126 |  |  | $56,342,010 |  |  | $115,471,071
(1) | Amount included here is the amount in the “Total” column from the Summary Compensation Table (“SCT”) for the principal executive officer (“PEO”) for the applicable year. For 2020-2023, our PEO was Dr. Gomez. For 2024, our PEO was Dr. Gomez until his retirement effective January 26, 2024 and Dr. Nguyen for the remainder of the fiscal year.
(2) | In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Compensation Actually Paid to PEO:
Year |  |  | Reported Summary Compensation Table for PEO |  |  | Reported Value of Equity Awards |  |  | Total Equity Award Adjustments(a) |  |  | Compensation “Actually Paid” to PEO
2024 |  |  | $4,588,317 |  |  | $(2,715,848) |  |  | $3,768,042 |  |  | $5,640,511
2023 |  |  | $1,825,856 |  |  | — |  |  | — |  |  | $1,825,856
2022 |  |  | $1,738,912 |  |  | — |  |  | — |  |  | $1,738,912
2021 |  |  | $1,688,264 |  |  | — |  |  | — |  |  | $1,688,264
2020 |  |  | $1,639,090 |  |  | — |  |  | — |  |  | $1,639,090
a) | The amounts added or deducted in calculating the total equity award adjustments are as follows:
Year |  |  | Year-End Fair Value of Equity Awards Granted During Applicable Year |  |  | Fair Value of Equity Awards Granted and Vested in the Applicable Year |  |  | Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End |  |  | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year |  |  | Total Equity Value Reflected in Compensation Actually Paid
2024 |  |  | $3,362,329 |  |  | $405,713 |  |  | — |  |  | — |  |  | $3,768,042
2023 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
2022 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
2021 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
2020 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
(3) | Amount included here is the average of the amounts in the “Total” column from the SCT for the applicable year for each of the other non-PEO NEOs. For 2024, our non-PEO NEOs were Mr. Luckshire, Dr. Hruby, Mr. Miller and Dr. Varma. For 2023, our non-PEO NEOs were: Mr. Luckshire, Dr. Hruby and Dr. Varma. For 2022, 2021 and 2020, our non-PEO NEOs were Mr. Luckshire, Dr. Hruby and Ms. Robin E. Abrams (former General Counsel and Chief Administrative Officer). The 2022 amount was impacted by the resignation of Ms. Abrams, effective April 18, 2022. The 2023 amount includes compensation paid to Dr. Varma, pro-rated based on his commencement date with the Company.
(4) | In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Average Total Compensation for the NEOs as a group for each year to determine the compensations “actually paid”.
Year |  |  | Reported Summary Compensation Table for Non-PEO NEOs |  |  | Average Reported Value of Equity Awards |  |  | Total Average Equity Award Adjustments(a) |  |  | Average Compensation “Actually Paid” to Non-PEO NEOs
2024 |  |  | $1,412,611 |  |  | $(304,473) |  |  | $243,744 |  |  | $1,351,882
2023 |  |  | $1,399,930 |  |  | $(283,333) |  |  | $256,881 |  |  | $1,373,478
2022 |  |  | $993,871 |  |  | — |  |  | — |  |  | $993,871
2021 |  |  | $1,285,045 |  |  | — |  |  | $(16,000) |  |  | $1,269,045
2020 |  |  | $1,280,950 |  |  | — |  |  | $73,779 |  |  | $1,354,729
a) | The amounts added or deducted in calculating the total average equity award adjustments are as follows:
Year |  |  | Year-End Fair Value of Equity Awards Granted During Applicable Year |  |  | Change in Fair Value as of Year- End of Any Prior Year Awards that Remain Unvested as of Year-End |  |  | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year |  |  | Total Equity Value Reflected in Compensation Actually Paid
2024 |  |  | $199,336 |  |  | $7,715 |  |  | $36,693 |  |  | $243,744
2023 |  |  | $256,881 |  |  | — |  |  | — |  |  | $256,881
2022 |  |  | — |  |  | — |  |  | — |  |  | —
2021 |  |  | — |  |  | — |  |  | $(16,000) |  |  | $(16,000)
2020 |  |  | — |  |  | $44,445 |  |  | $29,334 |  |  | $73,779
(5) | The peer group, for purposes of this analysis, is the Nasdaq Biotechnology Index. The company’s stock performance relative to the Nasdaq Biotechnology Index is disclosed in the Company’s Form 10-K.
(6) | Product Sales and Supportive Services Revenues is a financial measure that is consistent with U.S. GAAP that is considered by the Company as part of its executive compensation program. The Compensation Committee reviews a variety of performance goals and metrics for the purpose of awarding compensation to executive officers that are consistent with the Company’s overall compensation philosophy and the long-term interests of its stockholders. Among these, the Compensation Committee has identified Product Sales and Supportive Services Revenues as the most important financial performance measure (that is not otherwise required to be disclosed in the table above) used by the Company to link compensation actually paid to its NEOs for the year ended December 31, 2024 to the Company’s performance.
Company Selected Measure Name |  |  | Product Sales and Supportive Services Revenues |  |  |  |
Named Executive Officers, Footnote |  |  |
(1) | Amount included here is the amount in the “Total” column from the Summary Compensation Table (“SCT”) for the principal executive officer (“PEO”) for the applicable year. For 2020-2023, our PEO was Dr. Gomez. For 2024, our PEO was Dr. Gomez until his retirement effective January 26, 2024 and Dr. Nguyen for the remainder of the fiscal year.
(3) | Amount included here is the average of the amounts in the “Total” column from the SCT for the applicable year for each of the other non-PEO NEOs. For 2024, our non-PEO NEOs were Mr. Luckshire, Dr. Hruby, Mr. Miller and Dr. Varma. For 2023, our non-PEO NEOs were: Mr. Luckshire, Dr. Hruby and Dr. Varma. For 2022, 2021 and 2020, our non-PEO NEOs were Mr. Luckshire, Dr. Hruby and Ms. Robin E. Abrams (former General Counsel and Chief Administrative Officer). The 2022 amount was impacted by the resignation of Ms. Abrams, effective April 18, 2022. The 2023 amount includes compensation paid to Dr. Varma, pro-rated based on his commencement date with the Company.
Peer Group Issuers, Footnote |  |  |
(5) | The peer group, for purposes of this analysis, is the Nasdaq Biotechnology Index. The company’s stock performance relative to the Nasdaq Biotechnology Index is disclosed in the Company’s Form 10-K.
PEO Total Compensation Amount |  |  | $ 4,588,317 | $ 1,825,856 | $ 1,738,912 | $ 1,688,264 | $ 1,639,090
PEO Actually Paid Compensation Amount |  |  | $ 5,640,511 | 1,825,856 | 1,738,912 | 1,688,264 | 1,639,090
Adjustment To PEO Compensation, Footnote |  |  |
(2) | In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Compensation Actually Paid to PEO:
Year |  |  | Reported Summary Compensation Table for PEO |  |  | Reported Value of Equity Awards |  |  | Total Equity Award Adjustments(a) |  |  | Compensation “Actually Paid” to PEO
2024 |  |  | $4,588,317 |  |  | $(2,715,848) |  |  | $3,768,042 |  |  | $5,640,511
2023 |  |  | $1,825,856 |  |  | — |  |  | — |  |  | $1,825,856
2022 |  |  | $1,738,912 |  |  | — |  |  | — |  |  | $1,738,912
2021 |  |  | $1,688,264 |  |  | — |  |  | — |  |  | $1,688,264
2020 |  |  | $1,639,090 |  |  | — |  |  | — |  |  | $1,639,090
a) | The amounts added or deducted in calculating the total equity award adjustments are as follows:
Year |  |  | Year-End Fair Value of Equity Awards Granted During Applicable Year |  |  | Fair Value of Equity Awards Granted and Vested in the Applicable Year |  |  | Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End |  |  | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year |  |  | Total Equity Value Reflected in Compensation Actually Paid
2024 |  |  | $3,362,329 |  |  | $405,713 |  |  | — |  |  | — |  |  | $3,768,042
2023 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
2022 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
2021 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
2020 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
Non-PEO NEO Average Total Compensation Amount |  |  | $ 1,412,611 | 1,399,930 | 993,871 | 1,285,045 | 1,280,950
Non-PEO NEO Average Compensation Actually Paid Amount |  |  | $ 1,351,882 | 1,373,478 | 993,871 | 1,269,045 | 1,354,729
Adjustment to Non-PEO NEO Compensation Footnote |  |  |
(4) | In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Average Total Compensation for the NEOs as a group for each year to determine the compensations “actually paid”.
Year |  |  | Reported Summary Compensation Table for Non-PEO NEOs |  |  | Average Reported Value of Equity Awards |  |  | Total Average Equity Award Adjustments(a) |  |  | Average Compensation “Actually Paid” to Non-PEO NEOs
2024 |  |  | $1,412,611 |  |  | $(304,473) |  |  | $243,744 |  |  | $1,351,882
2023 |  |  | $1,399,930 |  |  | $(283,333) |  |  | $256,881 |  |  | $1,373,478
2022 |  |  | $993,871 |  |  | — |  |  | — |  |  | $993,871
2021 |  |  | $1,285,045 |  |  | — |  |  | $(16,000) |  |  | $1,269,045
2020 |  |  | $1,280,950 |  |  | — |  |  | $73,779 |  |  | $1,354,729
a) | The amounts added or deducted in calculating the total average equity award adjustments are as follows:
Year |  |  | Year-End Fair Value of Equity Awards Granted During Applicable Year |  |  | Change in Fair Value as of Year- End of Any Prior Year Awards that Remain Unvested as of Year-End |  |  | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year |  |  | Total Equity Value Reflected in Compensation Actually Paid
2024 |  |  | $199,336 |  |  | $7,715 |  |  | $36,693 |  |  | $243,744
2023 |  |  | $256,881 |  |  | — |  |  | — |  |  | $256,881
2022 |  |  | — |  |  | — |  |  | — |  |  | —
2021 |  |  | — |  |  | — |  |  | $(16,000) |  |  | $(16,000)
2020 |  |  | — |  |  | $44,445 |  |  | $29,334 |  |  | $73,779
Compensation Actually Paid vs. Total Shareholder Return |  |  | The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) cumulative total shareholder return on the Common Stock and cumulative total shareholder return on the stock of NASDAQ Biotech Composite Index for the last five completed fiscal years is shown in Figure 1. Figure 1: Compensation Actually Paid versus Total Shareholder Return (“TSR”) |  |  |  |
Compensation Actually Paid vs. Net Income |  |  | The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) net income of the Company for the last five completed fiscal years is shown in Figure 2. Figure 2: Compensation Actually Paid versus Net Income |  |  |  |
Compensation Actually Paid vs. Company Selected Measure |  |  | The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) product sales and supportive services revenues of the Company for the last five completed fiscal years is shown in Figure 3. Figure 3: Compensation Actually Paid versus Product Sales and Supportive Services Revenues |  |  |  |
Total Shareholder Return Vs Peer Group |  |  | The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) cumulative total shareholder return on the Common Stock and cumulative total shareholder return on the stock of NASDAQ Biotech Composite Index for the last five completed fiscal years is shown in Figure 1. Figure 1: Compensation Actually Paid versus Total Shareholder Return (“TSR”) |  |  |  |
Tabular List, Table |  |  | List of Performance Measures The Company utilizes other important financial measures to consider for compensation actually paid to its NEOs performance as set forth in the table below.
Total Product Sales and Supportive Services Revenues
Operating Income (Pre-Tax)
Total Revenues
International Sales Revenue
Net Income
Diluted Earnings per Share
Relative TSR
Total Shareholder Return Amount |  |  | $ 159 | 135 | 164 | 158 | 152
Peer Group Total Shareholder Return Amount |  |  | 114 | 115 | 111 | 125 | 126
Net Income (Loss) |  |  | $ 59,214,216 | $ 68,068,826 | $ 33,904,806 | $ 69,450,766 | $ 56,342,010
Company Selected Measure Amount |  |  | 133,330,181 | 130,668,209 | 86,661,583 | 126,802,536 | 115,471,071
PEO Name | Dr. Gomez | Dr. Nguyen |  | Dr. Gomez. | Dr. Gomez. | Dr. Gomez. | Dr. Gomez.
Equity Awards Adjustments, Footnote |  |  |
a) | The amounts added or deducted in calculating the total equity award adjustments are as follows:
Year |  |  | Year-End Fair Value of Equity Awards Granted During Applicable Year |  |  | Fair Value of Equity Awards Granted and Vested in the Applicable Year |  |  | Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End |  |  | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year |  |  | Total Equity Value Reflected in Compensation Actually Paid
2024 |  |  | $3,362,329 |  |  | $405,713 |  |  | — |  |  | — |  |  | $3,768,042
2023 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
2022 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
2021 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
2020 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
a) | The amounts added or deducted in calculating the total average equity award adjustments are as follows:
Year |  |  | Year-End Fair Value of Equity Awards Granted During Applicable Year |  |  | Change in Fair Value as of Year- End of Any Prior Year Awards that Remain Unvested as of Year-End |  |  | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year |  |  | Total Equity Value Reflected in Compensation Actually Paid
2024 |  |  | $199,336 |  |  | $7,715 |  |  | $36,693 |  |  | $243,744
2023 |  |  | $256,881 |  |  | — |  |  | — |  |  | $256,881
2022 |  |  | — |  |  | — |  |  | — |  |  | —
2021 |  |  | — |  |  | — |  |  | $(16,000) |  |  | $(16,000)
2020 |  |  | — |  |  | $44,445 |  |  | $29,334 |  |  | $73,779
Measure:: 1 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Total Product Sales and Supportive Services Revenues |  |  |  |
Measure:: 2 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Operating Income (Pre-Tax) |  |  |  |
Measure:: 3 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Total Revenues |  |  |  |
Measure:: 4 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | International Sales Revenue |  |  |  |
Measure:: 5 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Net Income |  |  |  |
Measure:: 6 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Diluted Earnings per Share |  |  |  |
Measure:: 7 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Relative TSR |  |  |  |
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | $ (2,715,848) | $ 0 | $ 0 | $ 0 | $ 0
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 3,768,042 | 0 | 0 | 0 | 0
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 3,362,329 | 0 | 0 | 0 | 0
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 0 | 0 | 0 | 0 | 0
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 405,713 | 0 | 0 | 0 | 0
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 0 | 0 | 0 | 0 | 0
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (304,473) | (283,333) | 0 | 0 | 0
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 243,744 | 256,881 | 0 | (16,000) | 73,779
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 199,336 | 256,881 | 0 | 0 | 0
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 7,715 | 0 | 0 | 0 | 44,445
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | $ 36,693 | $ 0 | $ 0 | $ (16,000) | $ 29,334

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii -Sentence B -Clause 1 -Subclause ii + Details
Name: | ecd_EqtyAwrdsAdjFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=4
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=5
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=6
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=7
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |